LARVOL Blog | 46% MSLs report Building New Relationships with KOLs as a Primary Challenge

Back to Blog

On March 10, 2021, the MSL Society hosted a live webinar to discuss the experience of MSL leaders and teams nearly a year to the day since the COVID-19 pandemic shut down their ability to meet with KOLs in person in much of the world. Our infographic below summarizes the key insights that emerged from the survey conducted by the MSL Society for the webinar. The survey highlighted whether MSL teams use digital solutions for KOL monitoring, and if these tools help manage time effectively or not.

Discover more insights in our blog Overcoming the Void of In-Person KOL Engagements and download this pdf for the full report.

Download attached file

Not rated

Allison Betof Warner, MD, PhD (she/her) 4

@DrBetofMDPhD

3743

Manhattan, NY

November 10, 2022

79% had reduction in disease. ORR 31%. Many responses deepen over time.

Not rated

Allison Betof Warner, MD, PhD (she/her) 3

@DrBetofMDPhD

3743

Manhattan, NY

November 10, 2022

Median DOR not yet reached. Median OS 13.9 mo. 12 mo OS was 54%. As typical with immunotherapy, we see a nice tail on the curve. #TIL #SITC22

Positive

Alex Shoushtari, MD

@alexshoushtari

2253

New York, USA

November 10, 2022

Important work on efficacy of TIL therapy lifileucel in PD-1 resistant #melanoma being presented at #SITC22. Pretty good durability for this heavy lift of a treatment.

Not rated

Allison Betof Warner, MD, PhD (she/her) 2

@DrBetofMDPhD

3743

Manhattan, NY

November 10, 2022

Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.

Positive

Hussein Tawbi, MD, PhD

@HTawbi_MD

1685

Houston, TX

November 10, 2022

Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated

Positive

Allison Betof Warner, MD, PhD (she/her) 1

DrBetofMDPhD

3744

Manhattan, NY

November 10, 2022

Where does this leave us with #TIL therapy for #melanoma? IMO, this response rate/durability justifies accelerated approval. Pts with PD-1 refractory melanoma need options. It’s FAR from a perfect tx but provides meaningful clinical benefit. What say you melanoma Twitterverse?

Not Rated

Sumanta K. Pal, MD, FASCO

@montypal

15083 Followers

Los Angeles, CA

November 8, 2022

Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX #CTX130 in #kidneycancer in the @sitcancer #PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims @DrBenTran @HaanenJohn #SamerSrour& co-Is! t.co/aDnhG9n92A

not rated

Shilpa Gupta

@Shilpaonc

5095 Followers

Cleveland, OH

November 8, 2022

@montypal @cityofhopeoc @CRISPRTX @sitcancer @neerajaiims @DrBenTran @HaanenJohn @DrChoueiri @TiansterZhang @tompowles1 @brian_rini @AlbigesL @Uromigos @ERPlimackMD @drenriquegrande @PGrivasMDPhD Congrats Monty! Looking forward to hearing about this exciting first-in the field study!

Not Rated

Tian Zhang, MD, MHS

@TiansterZhang

6463 Followers

Dallas, TX

November 8, 2022

CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe

Not Rated

Moshe Ornstein MD

@MosheOrnsteinMD

1930 Followers

Cleveland, OH

November 8, 2022

Congrats @montypal and team! Great to see CAR T therapy coming to #RCC t.co/ypRHBC89Pt

Not Rated

Shuchi Gulati MD

@ShuchiGulati

12476 Followers

Seattle, WA

November 8, 2022

Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7